Market revenue in 2024 | USD 79.9 million |
Market revenue in 2030 | USD 61.6 million |
Growth rate | -4.5% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.82% in 2024. Horizon Databook has segmented the Denmark anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
The anti-vascular endothelial growth factor (anti-VEGF) therapeutics market in Denmark is evolving amid notable economic and health trends that support its growth potential. With a steady GDP and one of the highest standards of healthcare in Europe, Denmark's healthcare sector is well-equipped to handle increasing cases of retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy, macular edema, and retinal vein occlusion.
The aging population, coupled with rising diabetes rates, has contributed to a higher incidence of these vision-related conditions, fueling demand for effective anti-VEGF treatments. Local market competition has been further influenced by entrants such as Biogen, Amgen, Inc., and Coherus BioSciences, which are increasingly focusing on biosimilar versions to offer cost-effective alternatives.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Denmark anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account